SK287832B6 - Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. - Google Patents

Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. Download PDF

Info

Publication number
SK287832B6
SK287832B6 SK1585-2003A SK15852003A SK287832B6 SK 287832 B6 SK287832 B6 SK 287832B6 SK 15852003 A SK15852003 A SK 15852003A SK 287832 B6 SK287832 B6 SK 287832B6
Authority
SK
Slovakia
Prior art keywords
carnitine
acetyl
biotin
insulin
acid
Prior art date
Application number
SK1585-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK15852003A3 (sk
Inventor
Menotti Calvani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SK15852003A3 publication Critical patent/SK15852003A3/sk
Publication of SK287832B6 publication Critical patent/SK287832B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1585-2003A 2001-05-29 2002-05-24 Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. SK287832B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
SK15852003A3 SK15852003A3 (sk) 2004-04-06
SK287832B6 true SK287832B6 (sk) 2011-11-04

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1585-2003A SK287832B6 (sk) 2001-05-29 2002-05-24 Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus.

Country Status (18)

Country Link
US (2) US20040142879A1 (https=)
EP (1) EP1399142B1 (https=)
JP (1) JP4381685B2 (https=)
KR (1) KR20040010666A (https=)
AT (1) ATE333274T1 (https=)
CA (1) CA2448244C (https=)
CY (1) CY1105403T1 (https=)
CZ (1) CZ297743B6 (https=)
DE (1) DE60213237T2 (https=)
DK (1) DK1399142T3 (https=)
ES (1) ES2268053T3 (https=)
HU (1) HUP0400060A2 (https=)
IT (1) ITRM20010294A1 (https=)
MX (1) MXPA03010921A (https=)
PL (1) PL207522B1 (https=)
PT (1) PT1399142E (https=)
SK (1) SK287832B6 (https=)
WO (1) WO2002096410A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006266A (es) * 2000-12-15 2004-06-25 Sigma Tau Ind Farmaceuti Uso de l-carnitina como agente estabilizador de proteinas.
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
NZ579767A (en) * 2007-03-21 2012-04-27 Sigma Tau Ind Farmaceuti Acetyl L-carnitine, optionally combined with an antihypertensive drug or a statin, for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
DE60213237T2 (de) 2007-08-02
JP4381685B2 (ja) 2009-12-09
ITRM20010294A0 (it) 2001-05-29
MXPA03010921A (es) 2004-02-27
CY1105403T1 (el) 2010-04-28
EP1399142A1 (en) 2004-03-24
CA2448244C (en) 2010-11-02
HUP0400060A2 (hu) 2004-04-28
CZ297743B6 (cs) 2007-03-21
US8053472B2 (en) 2011-11-08
PL367630A1 (en) 2005-03-07
PT1399142E (pt) 2006-10-31
PL207522B1 (pl) 2010-12-31
ATE333274T1 (de) 2006-08-15
US20040142879A1 (en) 2004-07-22
KR20040010666A (ko) 2004-01-31
DK1399142T3 (da) 2006-10-30
CA2448244A1 (en) 2002-12-05
US20080269307A1 (en) 2008-10-30
JP2004532866A (ja) 2004-10-28
CZ20033221A3 (cs) 2004-06-16
DE60213237D1 (de) 2006-08-31
ES2268053T3 (es) 2007-03-16
WO2002096410A1 (en) 2002-12-05
ITRM20010294A1 (it) 2002-11-29
SK15852003A3 (sk) 2004-04-06
EP1399142B1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
US5157022A (en) Method for reducing blood cholesterol using arginine
ZA200701816B (en) Composition containing statins and omega -3 fatty acids
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
EP4331583A1 (en) Blood carnitine-increasing agent
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
AU2007348123B2 (en) Composition useful for the treatment of type 2 diabetes
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1547614B1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
HK1135030B (en) Composition useful for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130524